← Eichor
Study identifier: NCT07632274 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years

Condition: Pain  ·  Sponsor: HALEON

PhasePhase 1
Planned participants12
Who can joinAll sexes, 6 Years to 11 Years
Healthy volunteersYes

About this study

The purpose of this study will be to characterize the pharmacokinetic (PK) profile of the Fixed-Dose Combination (FDC) IBU 62.5 milligram (mg)/APAP 125 mg per 5 milliliter (mL) suspension in children 6 to 11 years of age, inclusive, to satisfy Pediatric Research Equity Act (PREA) requirements.

This description comes directly from the study's public registry record.

Talk to the study team

Haleon Response Center  ·  +441932959500  ·  ww.clinical-trial-register@haleon.com

Always discuss trial participation with your own doctor first.

Locations (1)

CenExel Salt LakeSalt Lake City, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07632274